New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:42 EDTMRKMerck announces new data from Phase 1b pembrolizumab study
Merck announced new data from the company’s large ongoing Phase 1b study evaluating pembrolizumab, Merck’s investigational anti-PD-1 antibody, as a single agent in 411 patients with advanced melanoma. Following treatment with pembrolizumab, the estimated overall survival rate at one year was 69% across all patients studied, including 74% in patients without prior ipilimumab therapy and 65% in patients who had progressive disease on or following ipilimumab. At 18 months, the estimated OS was 62%. The median OS has not been reached, with some patients receiving treatment with pembrolizumab as monotherapy for more than two years.
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 30, 2015
12:33 EDTMRKDividend-rich blue chips look attractive amid market volatility, Barron's says
Subscribe for More Information
August 26, 2015
08:53 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
August 23, 2015
12:35 EDTMRKBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
05:44 EDTMRKStocks with implied volatility movement; DIS MRK
Subscribe for More Information
August 20, 2015
11:33 EDTMRKLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
08:38 EDTMRKMerck says to present new analyses from IMPROVE-IT study
Subscribe for More Information
August 18, 2015
12:13 EDTMRKMerck recalls Temodar, Temozolomide bottles with cracked caps
Subscribe for More Information
08:03 EDTMRKMerck says FDA accepts sBLA for Keytruda
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use